A Natural Depsipeptide Antibiotic Binds the E-Site of the Bacterial Ribosome

Why It Matters

MKM introduces a new chemical scaffold that targets an untapped ribosomal site, offering a promising avenue to combat rising antibiotic resistance, especially in hard‑to‑treat Gram‑negative infections.

Key Takeaways

• Manikomycin (MKM) is a cyclic depsipeptide from Streptomyces rimosus.
• MKM binds the 50S ribosomal E‑site, blocking tRNA translocation.
• Shows potent activity against multidrug‑resistant Gram‑negative bacteria.
• Resistance arises via sbmA transporter loss or 23S rRNA deletions.
• Heterologous expression confirms the 67 kb man BGC produces MKM.

Pulse Analysis

The accelerating crisis of antimicrobial resistance has revived interest in natural product discovery, especially from actinomycetes that historically supplied most clinically used antibiotics. Traditional Waksman‑type screens fell out of favor as known scaffolds dominated, but advances in metabolomics, genome mining, and fractionation now enable researchers to unearth cryptic compounds hidden in microbial genomes. By applying these modern tools to a curated Streptomyces library, scientists identified manikomycin, a previously unknown cyclic depsipeptide with a distinctive cationic architecture that sets it apart from conventional peptide antibiotics.

High‑resolution cryogenic electron microscopy revealed that MKM occupies the E‑site of the bacterial 50S ribosomal subunit, a region not previously exploited by antibacterial agents. The peptide’s core ring inserts into a pocket formed by helices of 23S rRNA, forming multiple hydrogen bonds that clash with the CCA‑end of deacylated tRNA, thereby preventing the essential translocation step of protein synthesis. This mechanism was corroborated by toe‑printing, cell‑free translation assays, and ribosome profiling, which together showed selective inhibition of bacterial translation with minimal impact on eukaryotic ribosomes. The structural insights also explain why common resistance mutations in ribosomal RNA or the bL35 protein diminish MKM binding, yet the overall frequency of resistance remains exceptionally low.

Clinically, MKM’s ability to kill multidrug‑resistant Gram‑negative pathogens while sparing human cells positions it as a strong candidate for next‑generation antibiotic development. Its novel binding site circumvents existing resistance pathways, and the successful heterologous expression of its 67 kb biosynthetic gene cluster paves the way for scalable production and engineering of analogues. Continued pre‑clinical evaluation will focus on pharmacokinetics, toxicity, and the potential to combine MKM with other agents to broaden its therapeutic window, offering hope against infections that currently lack effective treatments.